Search Results
346 Results Found for “non–small-cell lung cancer”
ASCO 2026 showed that thoracic oncology is moving beyond promising signals and increasingly closer to practice-changing evidence across multiple fields — from bispecific antibodies and ADC-based combinations to targeted therapy in both metastatic and peri-operative settings. In this piece, Dr Federico Monaca breaks down eight major abstracts from ASCO26, highlighting their take-aways and considering their potential relevance for clinical practice.
The five selected Plenary late-breaking abstracts at the ASCO 2026 Annual Meeting in Chicago showcased some of the meeting’s most practice-influencing data. Across prostate cancer, sarcoma, lung cancer and pancreatic cancer, these phase 3 studies demonstrated meaningful improvements in survival outcomes, highlighting the growing impact of perioperative intensification, precision oncology and novel targeted therapies in difficult-to-treat disease settings.
This issue of touchREVIEWS in Oncology & Haematology brings together a diverse collection of articles reflecting the growing complexity of cancer care and the continued evolution of precision medicine across tumour types. From rare malignancies and treatment-related challenges to emerging ...
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide.1 Over the past two decades, the molecular characterization of NSCLC has transformed the therapeutic landscape by enabling the development of targeted therapies that have significantly improved outcomes ...
Small bowel adenocarcinoma (SBA) is a rare gastrointestinal malignancy, accounting for about 1–3% of gastrointestinal cancers.1,2 Its reported incidence has increased in recent decades, likely reflecting improved detection by balloon-assisted and capsule endoscopy and the more widespread use of cross-sectional imaging.3,4 ...
In this touchONCOLOGY Future Leaders 2026 interview, Dr Lenz reflects on the mentorship that shaped his commitment to oncology, the role of research in exposing inequities in cancer care, and why ensuring equitable access to innovation will define the future of the field.
2025 has brought exciting developments in oncology, with groundbreaking research and real-world progress showcased at ASCO, ESMO, EHA, ASH and many more leading conferences around the world. We asked our key faculty to share what they believe has been most impactful so far this year – here’s what they told us.
Immune checkpoint inhibitors (ICIs) act by blocking inhibitory pathways such as programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), thereby restoring T-cell activity and promoting tumour cell destruction.1,2 The ability of tumours ...
Discover how everyday choices—from what you eat to how you manage stress—can significantly shape long-term cancer prevention. This article explores the powerful, evidence-based impact of nutrition, physical activity, sleep, and social connection on lowering cancer risk and supporting healthier aging. Learn what the world’s longest-living communities can teach us about prevention—and why small lifestyle changes can make a big difference.
The intestinal microbiota, composed of approximately 1,000 species and over 100 trillion micro-organisms, plays a vital role in host physiology, including metabolism, barrier function and immune regulation.1 Disruption of this delicate host–microbiota balance – known as dysbiosis – has been implicated in the ...
Early-onset lung cancer is typically defined as occurring in individuals aged 18–50 years, although there is no universally accepted definition.1–3 This entity, though rare, poses unique diagnostic and therapeutic challenges. This article synthesizes current evidence on the unique features and management ...
At WCLC 2025, final FLAURA2 results revealed that osimertinib plus chemotherapy significantly improves overall survival in EGFR-mutant advanced non-small cell lung cancer (NSCLC), extending median survival to nearly four years. Experts stress the practice-changing impact, while highlighting the importance of tailoring treatment to patient fitness, comorbidities, and individual goals.
Dr Federico Monaca discusses the role of consolidative thoracic radiotherapy after chemo-immunotherapy in ES-SCLC, highlighting improved chest control but uncertain survival impact. He also reflects on key WCLC 2025 updates, including DLL3-targeted therapies, novel immunotherapy combinations, and biomarker-driven strategies offering fresh hope in small cell and non-small cell lung cancers.
Dr Igor Gómez-Randulfe discusses new real-world evidence on second-line carboplatin plus pemetrexed after osimertinib in EGFR-mutant NSCLC. The retrospective analysis highlights modest response rates and short overall survival, reinforcing the need for more effective strategies and raising critical questions about sequencing, intensification, and resistance profiling.
Cervical cancer (CC) is the fourth most common cancer among women worldwide, with an estimated 604,000 new cases and 342,000 CC-related deaths in 2020.1# Approximately 90% of CCs are caused by infection with human papillomavirus (HPV).2 Even though the adoption of both primary (HPV ...
With #ASCO25 still fresh in our minds, touchONCOLOGY Editorial Board members Dr Fatemeh Ardeshir-Larijani (Emory School of Medicine, Atlanta, GA, USA) and Dr Gabirel Lenz (Hospital Regional Terezinha Gaio Basso, São Miguel Do Oeste, Brazil) reflect on their top key breakthroughs and take-aways from the conference in non-small cell lung cancer (NSCLC).
We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
